The Food and Drug Administration approved the first drug to treat the complete spectrum of narcolepsy type 1 symptoms — including cataplexy, the sudden loss of muscle tone triggered by emotion — the agency announced Aug. 5.
An estimated 135,000 to 200,000 Americans have narcolepsy type 1. Previous treatments addressed symptoms separately rather than the full clinical picture, leaving many patients managing multiple medications.
The approval is classified as first-in-class, meaning no other drug operates by the same mechanism, the FDA said. The designation signals a fundamentally new approach to treating the neurological sleep disorder.
Narcolepsy type 1 causes excessive daytime sleepiness, cataplexy, sleep paralysis and hallucinations. Patients frequently face years of misdiagnosis and inadequate treatment, with the average time from symptom onset to diagnosis stretching seven to 10 years.
The condition profoundly affects daily functioning, impairing the ability to work, drive and maintain social relationships. A comprehensive treatment that addresses the full symptom profile represents a meaningful advance in the neurology field.
The manufacturer of the newly approved drug was not specified in the FDA’s summary announcement. The drug received review through the agency’s standard new drug application process.